聚乙二醇化服务

PEGylation Services

JenKem Technology’s dedicated and experienced customer support group can help you identify the right high quality PEG derivatives for your PEGylation needs. JenKem Technology’s experienced R&D chemists will perform the PEGylation service efficiently for the highest quality PEGylated products in the shortest amount of time.
Currently JenKem Technology provides  two service models to meet our customer’s unique PEGylation needs:

Service model 1. PEGylation services provided as a regular end-product.
JenKem Technology will PEGylate your molecule and deliver your PEGylated product with a certificate of analysis, as a regular end-product, for further testing at your site. This is recommended for an initial evaluation of PEGylation approaches.

Service model 2. Complete PEGylation method development service.
Under this service model, JenKem will provide your PEGylated sample, as well as the complete PEGylation method development package, including all developed analytical methods for characterization of your PEGylated product, up to pre-clinical stage. 

北京键凯科技股份有限公司（证券代码688356，证券简称键凯科技）是2001年10月注册成立的致力于医用药用聚乙二醇衍生物产业化的高新技术企业，注册于北京市海淀区。
 

目前，公司已在天津开发区西区生物医药园建成占地15000多平方米的医用药用聚乙二醇衍生物的开发及产业化基地，在辽宁省盘锦市精细化工产业园建成了高纯度医用药用聚乙二醇材料的研发与全自动生产线。 目前公司及子公司天津键凯科技有限公司、辽宁键凯科技有限公司均获得高新技术企业认证，是国内外为数不多能进行高纯度和低分散度的医用药用聚乙二醇及活性衍生物工业化生产的公司，填补了国内长期缺乏规模化生产的高质量医用药用聚乙二醇及其衍生物这一空白，也是全球市场的主要新兴参与者。截至2021年2月，键凯科技已获批77项中国及世界发明专利，另有45项专利正在申请中。

键凯科技现已支持我国境内7个已上市的聚乙二醇修饰药物中4款药物的研发和生产，为数家国际医药企业提供其三类医疗器械生产所需的医用药用聚乙二醇及其活性衍生物。除此之外，公司还支持了多家国内国际药企及医疗器械企业的数十个II、III期临床项目，拥有800余家国际客户及300余家国内客户。

公司已于2020年8月26日正式登陆上海证券交易所科创板。